Generation of new lead compounds with drug-like properties by derivatization of existing drugs

Access to efficient drugs to treat diseases that affect Canadians is among the highest priorities of our society. The development of new medicinal agents depends on the access to small molecules capable of interacting with biological targets associated with those diseases. These small molecules are typically identified by screening large collections of synthetic compounds. Paraza Pharma Inc. is an innovative drug discovery company that is involved in optimization of early drug candidates for unmet medical needs in alliance with biotechnology and pharmaceutical companies. The objective of this project is to use an existing antibioactive drug to generate new high quality molecules that will serve as modulators of other biological targets. By using an existing compound for drug development, the goal is to generate new molecules that already possess excellent drug-like properties and low cytotoxicity. Throughout this project, derivatize a bioactive molecule using chemical reactions that were developed in our laboratories at UQÀM. This project will contribute to the training of one graduate student and will provide the company with a library of new molecules for testing against other targets using proprietary
biochemical or cellular assays.

Faculty Supervisor:

Alexandre Gagnon

Student:

Partner:

Paraza Pharma Inc

Discipline:

Life Sciences

Sector:

Manufacturing; Professional, scientific and technical services

University:

Université du Québec à Montréal

Program: